Leanne Stevenson

Belfast, NIR, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Journal: ESMO open

Published: May 23, 2024

Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma.

Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma.

Journal: Scientific reports

Published: February 02, 2024

Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches.

Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches.

Journal: Cancers

Published: May 06, 2022

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Journal: Gut

Published: September 19, 2018

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Journal: Oncotarget

Published: December 19, 2017

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.

Journal: Cell death & disease

Published: October 07, 2013

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 31, 2012

Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 04, 2012

Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Journal: Molecular cancer therapeutics

Published: June 06, 2012

A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.

A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.

Journal: Molecular cancer therapeutics

Published: October 27, 2011

Showing 1-10 of 10

Last Updated: 09/26/2026